Active Ingredient History
The Haemophilus influenzae type B vaccine, also known as Hib vaccine, is a vaccine used to prevent Haemophilus influenzae type b (Hib) infection. In countries that include it as a routine vaccine, rates of severe Hib infections have decreased more than 90%. It has therefore resulted in a decrease in the rate of meningitis, pneumonia, and epiglottitis. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Dengue (Phase 3)
Diphtheria (Phase 4)
Diphtheria-Tetanus-Pertussis Vaccine (Phase 3)
Diphtheria Toxoid (Phase 2)
Haemophilus Infections (Phase 4)
Haemophilus influenzae (Phase 4)
Haemophilus influenzae type b (Phase 4)
Healthy Volunteers (Phase 1)
Hepatitis B (Phase 3)
Immunization (Phase 3)
Influenza B virus (Phase 3)
Influenza, Human (Phase 3)
Meningitis (Phase 4)
Meningitis, Bacterial (Phase 3)
Meningococcal Infections (Phase 4)
Neisseria meningitidis (Phase 3)
Pertussis Vaccine (Phase 3)
Pneumonia, Staphylococcal (Phase 3)
Poliomyelitis (Phase 4)
Severe Dengue (Phase 3)
Streptococcal Infections (Phase 4)
Tetanus (Phase 4)
Whooping Cough (Phase 4)
Yellow Fever (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue